Meeting Coverage

Good Response With Nivolumab Plus Axitinib in Metastatic RCC

Feb 23, 2022

Combination treatment with nivolumab plus axitinib has achieved a high response rate in...

Biomarkers Predict Response to Immune Nivolumab (± Ipilimumab) in Advanced RCC

Feb 23, 2022

Biomarker analysis of the phase 2 TITAN-RCC trial identified specific immune cell-related...

Avelumab Plus Axitinib May Benefit High-Risk Early RCC

Feb 23, 2022

Results of the NeoAvAx trial indicate that the neoadjuvant combination of avelumab plus axitinib...

Health and Safety at ASCO GU 2022

Feb 16, 2022

Individual Accountability ASCO is committed to maintaining the health and safety of all ASCO Genitourinary Cancers Symposium attendees. We will be reviewing the latest Centers for Disease Control and Prevention and World Health...

Active Surveillance Helps Delay Systemic Therapy in Some With Metastatic Renal Cell Carcinoma

Feb 16, 2022

Active surveillance (AS) may be used effectively in a subgroup of patients(pts) with metastatic renal cell carcinoma (RCC) and indolent disease to postpone the commencement of systemic treatment without affecting long-term...

Mindfulness App Helps Address Psychosocial Distress in Patients With Metastatic Renal Cell Carcinoma

Feb 16, 2022

mRCC was linked to a high incidence of distress, a high degree of symptom load, and a wide range of quality-of-life impairments. A smartphone application aimed at enhancing mindfulness has been developed from a Mindfulness-Based...

Tele-mentoring Benefits Patients With Renal Cell Carcinoma

Feb 16, 2022

In recent years, the overall survival from metastatic renal cell carcinoma (RCC) has improved, mainly in part due to immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI). TKI and ICI had distinct and...

Response to Lenvatinib + Pembrolizumab in Advanced Renal Cell Carcinoma Regardless of Biomarker Status

Feb 16, 2022

Lenvatinib (lenva) + pembrolizumab (pembro) demonstrated encouraging antitumor activity and controllable safety characteristics in treatment-naive (n=23) or earlier cured metastatic RCC (n=105, initially medicated with immune...

ASCO GU Program Guide 2022

Feb 15, 2022

Thursday, Feb 17: Exhibits Open 10:00 AM – 9:45 PM EST Novel Treatment Implementation: Prostate-Specific Membrane Antigen Targeting and Beyond Primary Track: Prostate Cancer 10:45 AM – 12:30 PM EST Optimizing Management of...

ASCO GU 2022 Is Here!

Feb 15, 2022

Program at a Glance • Highly interactive sessions with multidisciplinary perspectives on new, innovative findings in the study, diagnosis, and treatment of GU malignancies. • Presentation of the latest novel science and...

ASH 2021: A Focus on Leukemia & Lymphoma

Jan 12, 2022

Focus on Lymphoma Leukemia

Take Our ASOPRS Quiz!

Jan 11, 2022

The ASOPRS 2022 PhysQuiz was created by the editorial staff at Physician’s Weekly. The ASOPRS 2022...

Patients With Non-Hodgkin’s Lymphoma Subtypes Incur High Hospital Costs

Jan 10, 2022

According to published data, patients with mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL) experience frequent relapses over the course of...

Venetoclax/Idelalisib Regimens Better Option After First-Line Ibrutinib for CLL/SLL

Jan 10, 2022

The establishment of ibrutinib as a preferred first-line treatment option makes it important to understand the treatment sequence following first-line ibrutinib and the patient characteristics of those treated with a second-line...

Delayed Start of Therapy Feasible in Some Patients With MCL

Jan 10, 2022

Currently, the effect of the diagnosis-to-treatment interval (DTI) on survival in patients with mantle cell lymphoma (MCL) has not been extensively examined. Researchers aimed to determine the feasibility of active surveillance...

Addition of Ibrutinib to Chemoimmunotherapy in CLL

Jan 8, 2022

The combination of fludarabine, cyclophosphamide, and rituximab (FCR) is the only regimen other than allotransplantation shown in studies to result in a significant chance of functional cure in very long-term follow-up for...